Delivery of stimulants through an inhalation route

A method of forming an ephedrine containing aerosol comprising:

• (a) heating a composition containing ephedrine coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the particles comprise less than 5 percent by weight of ephedrine degradation product, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a fenfluramine containing aerosol comprising:

• (a) heating a composition containing fenfluramine coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the particles comprise less than 5 percent by weight of fenfluramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a drug containing aerosol comprising:

• (a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the drug is selected from the group consisting of ephedrine and fenfluramine, and
• wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a drug containing aerosol comprising:

• (a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the drug is selected from the group consisting of ephedrine and fenfluramine, and
• wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a drug containing aerosol comprising:

• (a) heating a composition containing the drug coated on a solid support to form a vapor, and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the drug is selected from the group consisting of ephedrine and fenfluramine,
• wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and
• wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.